Quote | BioAtla Inc. (NASDAQ:BCAB)
Last: | $3.44 |
---|---|
Change Percent: | -1.16% |
Open: | $3.5 |
Close: | $3.44 |
High: | $3.55 |
Low: | $3.3254 |
Volume: | 703,194 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | BioAtla Inc. (NASDAQ:BCAB)
2024-03-26 19:21:09 ET BioAtla, Inc. (BCAB) Q4 2023 Earnings Conference Call March 26, 2024, 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Jay Short - Chairman, Chief Executive Officer and Co-Founder Richard Waldron - Chief F...
2024-03-26 16:42:37 ET Gainers: nCino ( NCNO ) +14% . Biomea Fusion ( BMEA ) +7% . Poseida Therapeutics ( PSTX ) +5% . Office Properties Income ( OPI ) +5% . Canopy Growth Corporation ( CGC ) +4% . Losers: Bow...
Message Board Posts | BioAtla Inc. (NASDAQ:BCAB)
Subject | By | Source | When |
---|---|---|---|
BCAB $2.47 Pfizer filed form 4 back in | DDHOUND | investorshub | 03/30/2023 5:31:49 PM |
BioAtla Announces $65 Million Underwritten Offering of its | crudeoil24 | investorshub | 11/04/2022 1:12:23 PM |
BioAtla Initiated at Market Outperform by JMP Securities | crudeoil24 | investorshub | 11/04/2022 1:02:44 PM |
BioAtla Reports Q3 2022 Cash Balance Of $178.1M | crudeoil24 | investorshub | 11/04/2022 1:01:55 PM |
In a report released today, Arthur He CFA | crudeoil24 | investorshub | 11/04/2022 1:00:53 PM |
News, Short Squeeze, Breakout and More Instantly...
BioAtla Inc. Company Name:
BCAB Stock Symbol:
NASDAQ Market:
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient d...